- Home
- NOV vs KRYS Comparison
NOV vs KRYS Comparison
Compare NOV & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOV
- KRYS
- Stock Information
- Founded
- NOV 1862
- KRYS 2015
- Country
- NOV United States
- KRYS United States
- Employees
- NOV N/A
- KRYS N/A
- Industry
- NOV Metal Fabrications
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NOV Industrials
- KRYS Health Care
- Exchange
- NOV Nasdaq
- KRYS Nasdaq
- Market Cap
- NOV 5.6B
- KRYS 4.6B
- IPO Year
- NOV 1996
- KRYS 2017
- Fundamental
- Price
- NOV $14.26
- KRYS $184.88
- Analyst Decision
- NOV Buy
- KRYS Strong Buy
- Analyst Count
- NOV 16
- KRYS 7
- Target Price
- NOV $19.60
- KRYS $220.00
- AVG Volume (30 Days)
- NOV 4.3M
- KRYS 297.9K
- Earning Date
- NOV 04-24-2025
- KRYS 05-05-2025
- Dividend Yield
- NOV 2.10%
- KRYS N/A
- EPS Growth
- NOV N/A
- KRYS 669.23
- EPS
- NOV 1.60
- KRYS 3.00
- Revenue
- NOV $8,870,000,000.00
- KRYS $290,515,000.00
- Revenue This Year
- NOV $0.35
- KRYS $60.34
- Revenue Next Year
- NOV $3.17
- KRYS $47.35
- P/E Ratio
- NOV $8.91
- KRYS $61.25
- Revenue Growth
- NOV 3.34
- KRYS 473.02
- 52 Week Low
- NOV $13.78
- KRYS $141.72
- 52 Week High
- NOV $21.20
- KRYS $219.34
- Technical
- Relative Strength Index (RSI)
- NOV 40.75
- KRYS 62.94
- Support Level
- NOV $13.78
- KRYS $175.98
- Resistance Level
- NOV $15.41
- KRYS $182.16
- Average True Range (ATR)
- NOV 0.49
- KRYS 7.28
- MACD
- NOV -0.07
- KRYS 0.57
- Stochastic Oscillator
- NOV 26.97
- KRYS 77.20
About NOV NOV Inc.
NOV (formerly National Oilwell Varco) is a leading supplier of oil and gas drilling rig equipment and products, such as downhole tools, drill pipe, and well casing. The company operates on a global scale, with international markets contributing nearly two thirds of its annual revenue.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.